Welcome to our dedicated page for Mural Oncology PLC SEC filings (Ticker: MURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates historical U.S. Securities and Exchange Commission filings for Mural Oncology plc (formerly Nasdaq: MURA), an Irish public limited company that operated as a clinical-stage immuno-oncology biotechnology company. These filings document key corporate events, including its strategic review, financial reporting, and acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation.
Among the notable documents are multiple Forms 8-K reporting material events. An August 4, 2025 Form 8-K furnished a press release with financial results for the quarter ended June 30, 2025 and described the company’s decision to discontinue all clinical development of nemvaleukin alfa and explore strategic alternatives. An August 20, 2025 Form 8-K detailed the transaction agreement under which XRA 5 Corp. agreed to acquire the entire issued and to be issued share capital of Mural Oncology via an Irish High Court sanctioned scheme of arrangement, outlining the cash consideration structure and key closing conditions.
A later Form 8-K dated October 24, 2025 summarized the results of the scheme meeting and extraordinary general meeting at which Mural Oncology shareholders approved the scheme of arrangement and related resolutions. That filing also noted that, based on these approvals, completion of the acquisition was expected during the fourth quarter of 2025, subject to customary conditions and the High Court’s sanction of the scheme.
For investors and researchers reviewing MURA’s regulatory history, these filings provide insight into how the company communicated its strategic shift away from active research and development, its cost-conservation measures, and the legal and shareholder processes leading to its acquisition. In addition to 8-Ks, Mural Oncology’s annual and quarterly reports referenced in these documents contain further discussion of business risks, clinical programs, and cash resources during the period before the acquisition.
On this platform, SEC filings for Mural Oncology are supplemented with AI-powered summaries that highlight key terms from lengthy documents, explain the implications of material agreements such as the transaction agreement with XOMA Royalty, and clarify voting outcomes and conditions described in Forms 8-K. Real-time integration with the EDGAR system ensures that material event filings, annual reports (Form 10-K), quarterly reports (Form 10-Q), and other disclosures are captured as they become available. Users can also review insider and major shareholder information where reported in accordance with applicable rules, alongside explanatory notes derived from the underlying filings.